Skip to main content
INOVIO PHARMACEUTICALS, INC. logo

INOVIO PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · INO ISIN · US45773H4092 LEI · 529900B9W875XDZXTM97 US Manufacturing
Open in API
Filings indexed 1,003 across all filing types
Latest filing 2023-11-28 Proxy Solicitation & In…
Country US United States of America
Listing US INO

About INOVIO PHARMACEUTICALS, INC.

https://www.inovio.com/

INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines. The company's core technology centers on designing proprietary DNA plasmids—small, circular DNA molecules that instruct the body's cells to produce specific, targeted proteins to combat disease. These DNA medicines are delivered into cells using the company's proprietary investigational CELLECTRA® smart devices. This platform is designed to enable in vivo protein production and achieve therapeutic effect without the use of chemical adjuvants, lipid nanoparticles, or viral vectors. The company's development pipeline targets HPV-related diseases, various cancers, and infectious diseases.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2023-11-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically a preliminary proxy statement for a Special Meeting of Stockholders of Inovio Pharmaceuticals, Inc. It includes detailed information about the meeting agenda, voting procedures, record date, and proposals to be voted on, such as a reverse stock split amendment and adjournment approval. The document is not an annual report, earnings release, or other financial report but is clearly a solicitation of shareholder votes with accompanying proxy materials. This matches the definition of a Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains detailed proxy information, not just an announcement or notice, so it is not an RPA or RNS. Therefore, the correct classification is PSI with high confidence.
2023-11-17 English
Regulatory Filings 2023
Regulatory Filings Classification · 90% confidence The provided document text appears to be heavily encoded or corrupted, containing mostly non-readable characters and no discernible content related to any specific financial filing type. There are no clear references to regulatory bodies, report titles, fiscal periods, or keywords that would indicate the nature of the document. Given the lack of meaningful content and the inability to identify any specific filing type, the document best fits the fallback category for miscellaneous or unclear filings, which is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable as a formal report or announcement.
2023-11-16 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement used for securities offerings under the Securities Act of 1933. It includes a prospectus describing the potential offering of common stock, preferred stock, debt securities, and warrants. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information about the securities offering, consistent with a registration statement prospectus. Hence, the classification is CAP with high confidence.
2023-11-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, by Inovio Pharmaceuticals, Inc. It announces the issuance of a press release with financial results for the quarter and nine months ended September 30, 2023. The text explicitly states that the press release is furnished as an exhibit and is incorporated by reference. The document itself does not contain the financial results or detailed financial statements but rather announces their release. The length of the document is 3596 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement of a report (press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain substantive financial data or the full earnings release text.
2023-11-09 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.